
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd demonstrates a strong positive outlook due to its innovative rhCollagen-based product, Collink.3D, which has shown superior performance in supporting structured tissue formation compared to traditional animal-derived matrices and is gaining scientific validation as a sustainable alternative for tissue engineering. The operationalization of a U.S.-based logistics center is expected to enhance sales prospects for both BioInk and rhCollagen, driven by increasing adoption rates among research institutions and tissue-engineering customers. Additionally, strategic partnerships, particularly with Allergan, and ongoing developments in the photocurable dermal filler program are likely to create significant revenue catalysts and strengthen the company's market position in regenerative medicine and medical aesthetics.
Bears say
CollPlant Biotechnologies Ltd's recent $2.0 million registered direct financing at a price of $1.25 per share highlights ongoing pressure on the company's equity, suggesting limited capacity for capital formation amid a challenging financial environment. The decision to reduce expectations for key products, including Dermal Fillers and BioInk, as well as the removal of Breast Implants from financial forecasts, indicates potential challenges in product development and market penetration. This combination of factors may undermine investor confidence and contribute to a downward valuation trend for the company.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares